-
Business
-
Policy & Business
-
-
Federal IT
-
Information Technology
-
-
State & Local
-
State & Local Government
-
-
Defense
-
Defense & Intelligence
-
-
Healthcare
-
Healthcare Policy & IT
-
-
Energy
-
Energy Policy & Technology
-
-
Education
-
Education Policy & Technology
-
FDA Approves Drug for Rare Blood Cancer
The Wall Street Journal (online registration required): Pharmacyclics Inc. PCYC +3.47% said it would sell its drug Imbruvica for more than $130,000 annually, making it one of the most expensive new cancer drugs on the market.
The drug, which will be co-marketed with Johnson & Johnson JNJ -0.24% and is known generically as ibrutinib, was approved by the U.S. Food and Drug Administration on Wednesday to treat patients with mantle cell lymphoma, a rare and aggressive type of blood cancer for which nearly 5,000 patients in the U.S. undergo treatment, according to Kantar Health, a consulting firm.
Tags
Share
Top Stories
- VA Says Its Renewed Infrastructure Review Will Focus on Building First
- Veterans Affairs Unveils Draft for $60B T4NG 2 Vehicle
- VA is Working to Add New Features to its Health and Benefits App
- Homelessness Among Veterans Has Been Cut in Half since 2010, VA Says
- Leidos partners with Accenture to deliver CDC cloud modernization
- Top 10 privacy and cybersecurity stories of 2022
- How to Solve the Healthcare Data Conundrum
- Top 10 privacy and cybersecurity stories of 2022
- Cardinal Health CIO Michelle Greene on simplifying transformation
- Get a handle on insider threats with industry intel
- Defense Department Health Plan Cuts Its Pharmacy Network by Nearly 15,000 Outlets
- Senator questions Mark Zuckerberg over Meta's healthcare data collection policies
- ‘I Can Go Anywhere’: How Service Dogs Help Veterans With PTSD
- Cutting Thousands of Medical Personnel Won’t Reduce Access to Care, Army Surgeon General Says
- VA ‘Moving Toward Full Compliance’ With Geospatial Data Law, Watchdog Finds
- NIH Injects $130M to Provide Quality Tools, Data for AI in Medicine
Whitepapers & Special Reports
i360Gov Newsletters
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe NowTrending
- Leidos partners with Accenture to deliver CDC cloud modernization
- Cardinal Health CIO Michelle Greene on simplifying transformation
- Army’s New Plan to ‘Transform’ Soldier Health Care with Technology
- VA Systems are Vulnerable to Cyber Intrusions Due to Lack of Effective Oversight, Report Says
- The business value of NLP: 5 success stories
- Defense Department Health Plan Cuts Its Pharmacy Network by Nearly 15,000 Outlets
- VA ‘Moving Toward Full Compliance’ With Geospatial Data Law, Watchdog Finds
- NIH Injects $130M to Provide Quality Tools, Data for AI in Medicine
Also in Healthcare Policy & IT
About
i360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Contact Us
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
Newsletters
Copyright © 2009-2024 i360Communications, LLC.